Natixis Advisors, L.P.
- SEC CIK
- 0001018331
- Latest filing
- Aug 14, 2026
PCRX holding history
Pacira BioSciences, Inc. in every 13F filed by Natixis Advisors, L.P., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
PCRX overviewAll 13F holders of PCRXFull Q2 2026 holdings
- Shares (Q2 2026)
- 17,248
- Value
- $437.0K
- % of portfolio
- <0.1%
- Quarters held
- 13
- Since Q4 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 17,248 | $437.0K | <0.1% | −8,308−32.5% | Reduced | Holders |
| Q1 2026 | 25,556 | $578.0K | <0.1% | +13,569+113.2% | Added | Holders |
| Q4 2025 | 11,987 | $310.0K | <0.1% | −4,125−25.6% | Reduced | Holders |
| Q3 2025 | 16,112 | $415.0K | <0.1% | +2,905+22.0% | Added | Holders |
| Q2 2025 | 13,207 | $316.0K | <0.1% | +68+0.5% | Added | Holders |
| Q1 2025 | 13,139 | $327.0K | <0.1% | +13,139 | New | Holders |
| Q3 2024 | 0 | $0 | 0.0% | −11,413−100.0% | Sold out | Holders |
| Q2 2024 | 11,413 | $327.0K | <0.1% | −404−3.4% | Reduced | Holders |
| Q1 2024 | 11,817 | $345.0K | <0.1% | +11,817 | New | Holders |
| Q3 2023 | 0 | $0 | 0.0% | −11,993−100.0% | Sold out | Holders |
| Q2 2023 | 11,993 | $481.0K | <0.1% | +1,638+15.8% | Added | Holders |
| Q1 2023 | 10,355 | $423.0K | <0.1% | +10,355 | New | Holders |
| Q4 2022 | 0 | $0 | 0.0% | −12,515−100.0% | Sold out | Holders |
| Q3 2022 | 12,515 | $666.0K | <0.1% | +12,515 | New | Holders |
| Q2 2022 | 0 | $0 | 0.0% | −12,898−100.0% | Sold out | Holders |
| Q1 2022 | 12,898 | $984.0K | <0.1% | +2,381+22.6% | Added | Holders |
| Q4 2021 | 10,517 | $633.0K | <0.1% | +10,517 | New | Holders |